



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,898
				Filing Date	3/15/2004
				First Named Inventor	Shafer et al.
				Art Unit	1614
Sheet	1	of	2	Examiner Name	
				Attorney Docket Number	03-03US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
CA		US-3,299,072	Issued 01-17-1967	Smith Kline & French Laboratories	
CA		US-3,966,940	Issued 06-29-1976	Bristol-Myers Company	
CA		US-4,457,933	Issued 07-03-1984	Bristol-Myers Company	
CA		US-4,489,065	Issued 12-18-1984	Valcor Scientific, Limited	
CA		US-4,661,492	Issued 04-28-1987	Reckitt & Colman Products Limited	
CA		US-4,769,372	Issued 09-06-1988	The Rockefeller University	
CA		US-4,785,000	Issued 11-15-1988	The Rockefeller University	
CA		US-5,130,126	Issued 07-14-1992	Nippon Oil & Fats Co., Ltd.	
CA		US-5,149,538	Issued 09-22-1992	Warner-Lambert Company	
CA		US-5,176,907	Issued 01-05-1993	The Johns Hopkins University School of Medicine	
CA		US-5,194,581	Issued 03-16-1993	Leong	
CA		US-5,236,714	Issued 08-17-1993	Alza Corporation	
CA		US-6,051,576	Issued 04-18-2000	University of Kentucky Research Foundation	
CA		US-6,228,863	Issued 05-08-2001	Euro-Celtique S.A.	
CA		US-6,277,384	Issued 08-21-2001	Euro-Celtique S.A.	
CA		US-6,375,957	Issued 04-23-2002	Euro-Celtique S.A.	
CA		US-6,451,806	Issued 09-17-2002	Aldor Corporation	
CA		US-6,475,494	Issued 11-05-2002	Euro-Celtique S.A.	
CA		US 2003/0022876 A1	01-30-2003	Ashton et al	
CA		US 2004/0058946 A1	03-25-2004	Buchwald et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
CA		GB 1 300 419	12-20-1972	Organon Laboratories Limited	_____	
CA		EP 1 258 246	11-20-2002	Euro-Celtique S.A.	_____	
CA		WO 02/094254 A2	11-28-2002	Endo Pharmaceuticals, Inc.	_____	

Examiner Signature	<u>ALY AKH</u>	Date Considered	<u>8/30/06</u>
--------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/800,898		
		Filing Date	3/15/2004		
		First Named Inventor	Shafer et al.		
		Art Unit	1614		
Sheet	2	of	2	Examiner Name	
				Attorney Docket Number	03-03US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CA		AGARWAL, V. and MISHRA, B.; "Design, Development, and Biopharmaceutical Properties of Buccoadhesive Compacts of Pentazocine;" <i>Drug Dev. Ind. Pharm.</i> ; June 1999; 25 (6); 701-709	
CA		BUCKETT, W. R.; "THE RELATIONSHIP BETWEEN ANALGESIC ACTIVITY, ACUTE TOXICITY AND CHEMICAL STRUCTURE INESTERS OF 14-HYDROXYCODEINONE;" <i>J Pharm Pharmacol</i> ; December 1964; 16 SUPPL-71T	
CA		BUCKETT, W. R.; FARQUHARSON, M. E.; and HAINING, C. G.; "THE ANALGESIC PROPERTIES OF SOME 14-SUBSTITUTED DERIVATIVES OF CODEINE AND CODEINONE;" <i>J Pharm Pharmacol</i> ; March 1964; 16 174-182	
CA		OKUDA, T.; TSUCHIYA, N.; WAKITA, K.; HATSUOKA, K.; KOGA, Y.; UEDA, S.; and KAETSU, I.; "[Prolonged Antinociceptive Effect After Epidural Injection of Polyethylene Glycol-Morphine Composites in Rats];" <i>Masui</i> ; May 1996; 45 (5); 571-575	
CA		NAGASE et al.; "The Facility of Formation of a Δ^8 Bond in Dihydromorphinone and Related Opiates;" <i>J. Org. Chem.</i> ; 1989, vol. 54; 4120-4125	
CA		HANSEN, H. C. and SPILLUM, A.; "Loss of Nitroglycerin During Passage Through Two Different Infusion Sets;" <i>Acta Pharm Nord.</i> ; 1991; 3 (3); 131-136	
CA		HOSZTAFI, S.; KOHEGYI, I.; SIMON, C.; and FURST, Z.; "Synthesis and Analgetic Activity of Nicotinic Esters of Morphine Derivatives;" <i>Arzneimittelforschung.</i> ; November 1993; 43 (11); 1200-1203	
CA		HUSSAIN, M. A.; AUNGST, B. J.; KOVAL, C. A.; and SHEFTER, E.; "Improved Buccal Delivery of Opioid Analgesics and Antagonists With Bitterless Prodrugs;" <i>Pharm Res</i> ; September 1988; 5 (9); 615-618	
CA		STINCHCOMB, A. L.; PALIWAL, A.; DUA, R.; IMOTO, H.; WOODARD, R. W.; and FLYNN, G. L.; "Permeation of Buprenorphine and Its 3-Alkyl-Ester Prodrugs Through Human Skin;" <i>Pharm Res</i> ; October 1996; 13 (10); 1519-1523	
CA		STINCHCOMB, A. L.; SWAAN, P. W.; EKABO, O.; HARRIS, K. K.; BROWE, J.; HAMMELL, D. C.; COOPERMAN, T. A.; and PEARSALL, M.; "Straight-Chain Naltrexone Ester Prodrugs: Diffusion and Concurrent Esterase Biotransformation in Human Skin;" <i>J Pharm Sci</i> ; December 2002; 91 (12); 2571-2578	

Examiner Signature	<u>ALLAKH</u>	Date Considered	<u>8/30/06</u>
--------------------	---------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.